Morphologic and biochemical changes in cartilage of foals treated with dexamethasone.
Epiphyseal and articular cartilages were examined in pony foals treated with intramuscular injections of either 0.5 mg dexamethasone per 100 kg bodyweight daily for 3, 8 or 11 months, or 5.0 mg per 100 kg for 11 months, and in horse foals treated with 5.0 mg per 100 kg for 20 weeks. The proximal femoral growth plates exhibited increased spatial separation between chondrocyte columns, narrowed zones of disorganized columnar and hypertrophic cartilage, abnormal penetration of hypertrophic cartilage by metaphyseal capillaries, retained cartilage in the spongiosa, distal terminal plate formation, transverse trabeculation, chondronecrosis and metaphyseal osteochondrosis dissecans. Destructive articular lesions were observed after 3 months of treatment with 0.5 mg per 100 kg bodyweight. Joint damage originated either at the joint surface or deep within the cartilage. Signs of surface deterioration included edema, fibrillation, enlargement of lacunae, pitting, shredding and erosions of cartilage. Inactivity of articular cartilage growth centers was common, with failure of epiphyseal capillaries to penetrate the lacunae in the calcified cartilage. Chondronecrosis adjacent to the calcification front was accompanied by cartilage ulceration and fracture. Intracartilaginous cysts and subchondral chondroid cysts were also observed. Healing responses included reparative chondrogenesis (focal cartilage hyperplasia), formation of fibrous or fibrocartilaginous "scars," subchondral osteopetrosis and epiphyseal marrow petrosis. Lactate dehydrogenase specific activities per chondrocyte, 35S uptake per cell and glycosaminoglycan contents of articular cartilages were all reduced 55% by 3 months of treatment. This inhibition of articular chondrocyte metabolism initiated cartilage degeneration. Surface destruction and osteochondrosis dissecans followed continued mechanical stress of compromised cartilage.
D000818:Animals; D001846:Bone Development / Q000187:drug effects; D001842:Bone and Bones / Q000473:pathology; D002356:Cartilage / Q000187:drug effects* / Q000473:pathology; D002357:Cartilage Diseases / Q000473:pathology / Q000662:veterinary*; D002358:Cartilage, Articular / Q000187:drug effects* / Q000473:pathology; D003907:Dexamethasone / Q000494:pharmacology*; D006734:Horse Diseases / Q000473:pathology*; D006736:Horses; D007592:Joint Diseases / Q000473:pathology / Q000662:veterinary*; D010007:Osteochondritis / Q000473:pathology / Q000662:veterinary*
D003907:Dexamethasone